Effect of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor (Vildagliptin) on Peripheral Nerves in Streptozotocin-induced Diabetic Rats

Archives of Medical Research

Volumn 40, Issue 7, 2009, Pages 536-544

  Jin, Heung Yong ^a   Liu, Wei Jing ^a   Park, Ji Hyun ^a   Baek, Hong Sun ^a   Park, Tae Sun ^a  

^a Research Institute of Clinical Medicine   (South Korea)

Author keywords

Diabetes; DPP IV inhibitor; GLP 1 pathway; Peripheral nerve

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GENE PRODUCT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; VILDAGLIPTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL STRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; EPIDERMIS CELL; FOOD INTAKE; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PERCEPTIVE THRESHOLD; PERIPHERAL NERVE; PROTEIN BLOOD LEVEL; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; WEIGHT CHANGE;

ADAMANTANE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EATING; ELECTRIC STIMULATION; EPIDERMIS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MALE; NERVE DEGENERATION; NITRILES; PERIPHERAL NERVES; PYRROLIDINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; UBIQUITIN THIOLESTERASE;

EID: 71649102751     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2009.09.005     Document Type: Article

References (30)

1. Argoff C.E., Cole B.E., Fishbain D.A., et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 81 suppl 4 (2006) S3-S11
2. Vinik A.I., and Mehrabyan A. Diabetic neuropathies. Med Clin North Am 88 (2004) 947-999 xi
3. Sima A.A., Thomas P.K., Ishii D., et al. Diabetic neuropathies. Diabetologia 40 suppl 3 (1997) B74-B77
4. Boulton A.J., Malik R.A., Arezzo J.C., et al. Diabetic somatic neuropathies. Diabetes Care 27 (2004) 1458-1486
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 837-853
6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 854-865
7. Argoff C.E., Backonja M.M., Belgrade M.J., et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 81 suppl 4 (2006) S12-S25
8. Siemionow M., and Demir Y. Diabetic neuropathy: pathogenesis and treatment. J Reconstr Microsurg 20 (2004) 241-252
9. Estall J.L., and Drucker D.J. Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des 12 (2006) 1731-1750
10. Nauck M.A., and Meier J.J. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 128 (2005) 135-148
11. Perry T., Lahiri D.K., Chen D., et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300 (2002) 958-966
12. Perry T., Holloway H.W., Weerasuriya A., et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 203 (2007) 293-301
13. Biswas S.C., Buteau J., and Greene L.A. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem Res 33 (2008) 1845-1851
14. Nakagawa A., Satake H., Nakabayashi H., et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110 (2004) 36-43
15. Holst J.J., and Deacon C.F. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol 4 (2004) 589-596
16. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26 (2003) 2929-2940
17. Holst J.J., and Deacon C.F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47 (1998) 1663-1670
18. Burkey B.F., Li X., Bolognese L., et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 315 (2005) 688-695
19. Kiso T., Nagakura Y., Toya T., et al. Neurometer measurement of current stimulus threshold in rats. J Pharmacol Exp Ther 297 (2001) 352-356
20. Beiswenger K.K., Calcutt N.A., and Mizisin A.P. Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem 110 (2008) 351-362
21. Apfel S.C. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med 107 (1999) 34S-42S
22. During M.J., Cao L., Zuzga D.S., et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9 (2003) 1173-1179
23. Kieffer T.J., and Habener J.F. The glucagon-like peptides. Endocr Rev 20 (1999) 876-913
24. Perry T., and Greig N.H. The glucagon-like peptides: a double-edged therapeutic sword?. Trends Pharmacol Sci 24 (2003) 377-383
25. Park C.W., Kim H.W., Ko S.H., et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 18 (2007) 1227-1238
26. Sokos G.G., Nikolaidis L.A., Mankad S., et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12 (2006) 694-699
27. Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 49 (2006) 253-260
28. Mari A., Sallas W.M., He Y.L., et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90 (2005) 4888-4894
29. Fricker B., Muller A., and Rene F. Evaluation tools and animal models of peripheral neuropathies. Neurodegener Dis 5 (2008) 72-108
30. Buteau J. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab 34 Suppl 2 (2008) S73-S77